INHIBRX BIOSCIENCES INC (INBX)
Health Care · Clinical-stage immuno-oncology biopharmaceuticals · NASDAQ
A clinical-stage biopharma company leveraging proprietary protein engineering to develop next-generation biologic therapeutics for hard-to-treat solid tumors.
What INHIBRX BIOSCIENCES INC does
Inhibrx is a clinical-stage biopharmaceutical company developing novel biologic therapeutics using proprietary modular protein engineering platforms. The company was separated from Inhibrx, Inc. in May 2024 following a spin-off and Sanofi acquisition of the INBRX-101 program, and now focuses on two lead oncology programs: ozekibart (INBRX-109), a tetravalent DR5 agonist, and INBRX-106, a hexavalent OX40 agonist, both in clinical development for solid tumors.
Themes: oncology / cancer immunotherapy, death receptor agonists (DR5), co-stimulatory agonists (OX40), protein engineering / synthetic biology, clinical-stage biopharmaceuticals
Fundamentals
- Price$103.63 as of 2026-08-21 close
- Market cap$1.5B as of 2026-08-21
- 1-year return+328.9% 2025-08-21 close $24.16 → 2026-08-21 close $103.63
- P/En/a negative earnings
- Net margin-5465.6% as of 2026-08-24
- ROE-269.6% as of 2026-08-24
- Debt / equity12.58 as of 2026-08-24
- Revenue growth (YoY)+550.0% FY2025 vs FY2024, SEC XBRL
- Revenue CAGR (3y)-15.0% SEC XBRL
- Beta3.08 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How INBX compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How INHIBRX BIOSCIENCES INC looks technically
INHIBRX BIOSCIENCES INC (INBX) is trading 19.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 274 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2026-07-09, pushing above its recent trading range. It is 33.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 19.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +19.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $91.43 | $91.43 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $86.56 | $86.56 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 274 trading days ago — a "golden cross", a bullish long-term signal | 274 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 19.7% above | +19.7% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 14.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 63.3 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($80.42 to $105.65) — its "stochastic" reading is 92 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 92.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 14 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $155.29 | $155.29 |
|---|---|---|
| From the 52-week high | it is 33.3% below its 52-week high (its highest price of the past year) | -33.3% |
| Above the 52-week low | it is 370.2% above its 52-week low (its lowest price of the past year) | +370.2% |
| Below the 52-week high | it is 33.3% below its highest point of the past year | 33.3% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-07-09, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 18 trading days ago | 18 sessions |
| All-time high | its highest closing price on record is $155.29 (set on 2026-04-22) | $155.29 |
| Given back of the 52-week move | over the past year its closes ranged ($23.00 to $141.84), and it has given back roughly a third of its rise from last year’s low — 32% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $64.59 to $68.40. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 32.1% |
| From the all-time high | it is 33.3% below its all-time high | -33.3% |
| Nearest price level | it is trading 4.2% above a support level at $99.27 — a price it turned at twice since 2026-05-12, most recently on 2026-06-18. Since 2024-08-21 it has 17 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.2% |
| All-time low | its lowest closing price on record is $7.67 (set on 2022-06-16) | $7.67 |
| Above the all-time low | it is 1251.1% above its all-time low | +1,251% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 68th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $6.29 between its high and its low — about 6.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $6.29 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $74.93 and $104.36 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $74.93 – $89.64 – $104.36 |
| Typical daily range (% of price) | its price moves about 6.1% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.1% |
| Stretch from the 200-day average | it is trading 2.7 daily ranges above its 200-day average price (19.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.92× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.6% |
|---|---|---|
| Open gap | it gapped 2.2% above the previous close 16 sessions ago and has not traded back through the level it left behind at 79.25 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.2% |
| Gap filled | a 2.8% gap down opened on 2026-08-20 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 16.0 percentage points (the stock gained 18.3% while the market gained 2.3%) | +15.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 9.4 percentage points (the stock lost 6.3% while the market gained 3.1%) | -9.4% |
| vs market, 6 months | over the past 6 months this stock beat the market by 20.7 percentage points (the stock gained 31.8% while the market gained 11.1%) | +20.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 308.5 percentage points (the stock gained 328.9% while the market gained 20.5%) | +308.4% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 21.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 8% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $96.38 — a volume-weighted average of daily closes over 154 sessions, not a true tick-by-tick VWAP. | +7.5% |
|---|
Price levels it has turned at before
INBX last closed at $103.63 on 2026-08-21. Since 2024-08-21 it has turned at 17 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $99.27 | Support | 4.2% below the last close | turned there twice · 2026-05-12 to 2026-06-18 |
| $94.52 | Support | 8.8% below the last close | turned there twice · 2025-12-08 to 2025-12-22 |
| $88.28 | Support | 14.8% below the last close | turned there twice · 2025-11-24 to 2026-02-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.67 mean, 1=Strong Buy…5=Strong Sell) — 2 analysts
- Mean price target$277.50 range $230.00 – $325.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for INBX
- Consensus EPS estimate-$2.39 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: both lead programs (ozekibart and INBRX-106) are in Phase 1-2 development with significant regulatory and efficacy hurdles ahead before any product approval or commercialization","Financial sustainability: company is pre-revenue and unprofitable with accumulated deficit of $279.6M as of Q1 2026, dependent on continued access to capital markets for financing operations and clinical development","Competition and intellectual property: entering crowded immuno-oncology market with established competitors and risk of patent invalidity or infringement claims against proprietary protein engineering platforms"]
What changed in the latest 10-Q
AI-assisted comparison of INBX's 10-Q filed 2026-05-14 against the prior one filed 2025-11-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references fiscal year ended December 31, 2025 (vs. December 31, 2024 in older filing)
- Newer filing announces April 2026 interim data from Phase 1/2 colorectal cancer study with 45 evaluable patients, 20% ORR, 5.5 months median PFS, 87% disease control rate
- Newer filing states ozekibart maintains manageable safety profile with diarrhea, fatigue, nausea as most common treatment-related adverse events, largely Grade 1-2
- Newer filing notes 68% of patients presented with liver metastases at baseline with no significant liver toxicity observed
- Newer filing states plan to meet with FDA in second half of 2026 regarding accelerated regulatory pathway for fourth-line colorectal cancer and first-line registrational trial
- Newer filing provides March 2026 Ewing sarcoma update with 31 evaluable patients, 64.5% ORR, 87.1% disease control rate, with responses ongoing in eight patients
- Newer filing states plan to complete Ewing sarcoma enrollment in second half of 2026 and meet with FDA regarding accelerated regulatory pathway if trends continue
- Newer filing states biologics license application submitted to FDA in April 2026 for chondrosarcoma (vs. plan to submit in Q2 2026 in older filing)
- Newer filing mentions May 2026 announcement of positive interim results from randomized first-line Phase 2 HexAgon study for INBRX-106
- Removed:
- Older filing contains extensive discussion of separation from Former Parent (Inhibrx, Inc.), spin-off of INBRX-101, merger with Sanofi subsidiary, and related restructuring transactions - removed in newer filing
- Older filing states chondrosarcoma trial completed full enrollment in July 2025 - not mentioned in newer filing
- Older filing provides detailed chondrosarcoma safety information including hepatotoxicity discussion, fatal event early in study, mitigation measures, 11.8% vs 4.5% treatment-related hepatic adverse events - not included in newer filing
- Older filing references January 2025 interim colorectal adenocarcinoma data with 10 of 13 evaluable patients and mention of one complete response - removed in newer filing with updated April 2026 data
- Reworded:
- Older filing lists indications as 'chondrosarcoma, colorectal cancer, Ewing sarcoma, and certain other solid tumor types' vs. newer filing listing 'colorectal cancer, Ewing sarcoma, chondrosarcoma, and certain other solid tumor types' (reordered)
- Newer filing describes chondrosarcoma trial as 'randomized, blinded, placebo-controlled, registrational trial' vs. older filing's 'registration-enabling Phase 2 trial'
- Newer filing refers to disease as 'locally advanced or metastatic, unresectable colorectal cancer' vs. older filing's 'advanced or metastatic, unresectable colorectal adenocarcinoma'
- Notes:
- Newer filing text is truncated at end of INBRX-106 section, limiting complete comparison of that program's discussion
- Older filing provides substantially more background on corporate separation/restructuring which is entirely absent from newer filing, suggesting different filing periods and company circumstances rather than content changes to program information
Risk Factors
- Added:
- Newer filing (2026-05-14) includes 'Issuance of warrants in connection with March 2026 Amendment to the 2025 Loan Agreement' with $1,289 value in stockholders' equity statement
- Newer filing (2026-05-14) shows 'Issuance of shares upon exercise of stock options' with 30 shares and $471 value in the three-month period
- Newer filing (2026-05-14) cash flow statement includes 'Proceeds from the issuance of debt' of $74,992 for three months ended March 31, 2026
- Newer filing (2026-05-14) includes supplemental disclosure of 'Fair value of warrants issued to lender in conjunction with Amended 2025 Loan Agreement' of $1,289
- Removed:
- Older filing (2025-11-14) includes 'Accounts receivable' line item ($110k as of Sept 30, 2025); newer filing (2026-05-14) does not separately report accounts receivable in balance sheet
- Older filing (2025-11-14) includes 'Receivables from related parties' line item ($0k as of Sept 30, 2025); newer filing (2026-05-14) does not separately show this item
- Older filing (2025-11-14) reports 'License fee revenue' ($1,300k for nine months ended Sept 30, 2025); newer filing (2026-05-14) shows no revenue in three-month period ended March 31, 2026
- Older filing (2025-11-14) includes 'Gain related to transaction with Acquirer' ($2,021,498k for nine months ended Sept 30, 2024); this item is not present in newer filing
- Older filing (2025-11-14) includes 'Loss on disposal of fixed assets' ($3k for nine months ended Sept 30, 2025); newer filing (2026-05-14) does not report this item
- Older filing (2025-11-14) includes 'Non-cash gain on transaction with Acquirer' adjustment in cash flows; newer filing (2026-05-14) does not include this adjustment
- Reworded:
- Older filing (2025-11-14) states company 'has a pipeline of novel biologic therapeutic candidates'; newer filing (2026-05-14) states company's 'current pipeline is focused on oncology' (added oncology focus specification)
- Newer filing (2026-05-14) references 'Annual Report on Form 10-K filed with the SEC on March 19, 2026' while older filing (2025-11-14) references fiscal year ended December 31, 2025 in different context
- Balance sheet comparison periods changed: older filing (2025-11-14) compares September 30, 2025 to December 31, 2024; newer filing (2026-05-14) compares March 31, 2026 to December 31, 2025
- Notes:
- The older filing provided is truncated at the Notes section and ends mid-sentence; comparison of notes content is therefore not possible
- Newer filing shows three-month financial results (Q1 2026) while older filing shows nine-month and quarterly results (through Q3 2025); direct period-to-period comparison of operating metrics is limited due to different reporting periods
- The 'Risk Factors' section itself is not provided in detail in either filing excerpt (only page references shown); substantive risk factor changes cannot be assessed from provided text
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Most recent open-market transaction: 2025-10-07. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about INBX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding INBX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 2,961,596
- Reported value $199,108,054
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
INBX had 3,341,210 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
INBX had 22.7% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 15.64 days to cover at the same settlement.
- Reported short interest (shares) 3,341,210
- Short interest (% of shares outstanding) 22.7%
- Prior settlement (shares) 3,433,872
- Reported change -2.7%
- Days to cover (reported) 15.64
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Bristol Myers Squibb (BMY)
- Genentech (ROG)
- Gilead Sciences (GILD)
- Merck & Co. (MRK)
- Novartis (NVS)
- Pfizer (PFE)
- Roche (ROG)
- Sanofi (SNY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare INBX vs…
INBX ranks in…
Frequently asked questions
What does INHIBRX BIOSCIENCES INC (INBX) do?
Inhibrx is a clinical-stage biopharmaceutical company developing novel biologic therapeutics using proprietary modular protein engineering platforms. The company was separated from Inhibrx, Inc. in May 2024 following a spin-off and Sanofi acquisition of the INBRX-101 program, and now focuses on two lead oncology programs: ozekibart (INBRX-109), a tetravalent DR5 agonist, and INBRX-106, a hexavalent OX40 agonist, both in clinical development for solid tumors.
What sector is INHIBRX BIOSCIENCES INC (INBX) in?
INHIBRX BIOSCIENCES INC (INBX) is classified in the Health Care sector. Its industry is Clinical-stage immuno-oncology biopharmaceuticals. It trades on NASDAQ.
Who are INHIBRX BIOSCIENCES INC's (INBX) competitors?
Notable peers of INHIBRX BIOSCIENCES INC (INBX) include Amgen, Bristol Myers Squibb, Genentech, Gilead Sciences and Merck & Co.. This peer set is informational only — not financial advice.
Is INHIBRX BIOSCIENCES INC (INBX) overbought or oversold right now?
INHIBRX BIOSCIENCES INC (INBX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on INBX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.